Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Pfizer Inc, Eli Lilly, Amgen and Biogen.

http://www.profits.zacks.com/
CHICAGO--(Business Wire)--
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day
the Zacks Equity Research analysts discuss the latest news and events impacting
stocks and the financial markets. Stocks recently featured in the blog include:
Bristol-Myers Squibb (NYSE: BMY), Pfizer Inc (NYSE: PFE), Eli Lilly (NYSE: LLY),
Amgen (Nasdaq: AMGN) and Biogen (Nasdaq: BIIB).

Get the most recent insight from Zacks Equity Research with the free Profit from
the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Friday`s Analyst Blog:

Drug Cos to Present at ASCO

Bristol-Myers Squibb (NYSE: BMY) will be presenting updated survival data of its
melanoma candidate, ipilimumab, from several phase II and phase III trials, both
as a monotherapy and in combination with chemotherapy. Bristol will also have
several presentations on Erbitux, including phase II data in combination with
cisplatin in non-small cell lung cancer.

Pfizer Inc (NYSE: PFE) will be presenting phase II data on Sutent in combination
with docetaxel in patients with previously untreated hormone refractory prostate
cancer.

Eli Lilly (NYSE: LLY) will be making more than 50 presentations at ASCO 2009
including several on Alimta in NSCLC and Gemzar in combination with cisplatin in
cervical cancer.

Amgen (Nasdaq: AMGN) plans a very busy ASCO as well. Most of these are data
presentations are results from testing Vectibix (panitumumab) in various stages
and combination regimens for metastatic colorectal cancer. The company plans
presentations by KRAS tumor status with Vectibix as well, plus several
combination studies testing Vectibix and AMG-655 in lung, colorectal, and
pancreatic cancer.

Biogen (Nasdaq: BIIB) will be presenting results from a phase II study comparing
volociximab and pegylated liposomal doxorubicin vs. doxorubicin alone in
recurrent ovarian or peritoneal cancer.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros
newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis
to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks.
Our analysts are organized by industry which gives them keen insights to
developments that affect company profits and stock performance. Recommendations
and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest
analysis from Zacks Equity Research. Subscribe to this free newsletter today:
http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in
1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns
in stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking system;
the Zacks Rank, which continues to outperform the market by nearly a 3 to 1
margin. The best way to unlock the profitable stock recommendations and market
insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of Profitable
ideas GUARANTEED to be worth your time! Register for your free subscription to
Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should
always research companies and securities before making any investments. Nothing
herein should be construed as an offer or solicitation to buy or sell any
security.

Zacks.com
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

Copyright Business Wire 2009